ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
NTRK2 is an oncogene and associated with microRNA-22 regulation in human gastric cancer cell lines.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Tetrahedral framework nucleic acids: Nanokeys unlocking a new era of precision biomedicine.Journal of advanced research · 2026Review
- NTRK2 promotes malignant progression and paclitaxel resistance of lung adenocarcinoma through targeting MYC/ABCF1 axis.Translational oncology · 2026Article
- The SLC26A4-AS1/NTRK2 axis in breast cancer: insights into the ceRNA network and implications for prognosis and immune microenvironment.Discover oncology · 2025Article
- A comprehensive bioinformatic evaluation of the NTRK family's potential as prognostic biomarkers in breast cancer.Bioinformatics advances · 2025Article
- CAP-RNAseq: an integrated pipeline for functional annotation and prioritization of co-expression clusters.Briefings in bioinformatics · 2024Article
- The synergistic effects of anoikis-related genes and EMT-related genes in the prognostic prediction of Wilms tumor.Frontiers in molecular biosciences · 2024Article
- Comprehensive Network Analysis Identified SIRT7, NTRK2, and CHI3L1 as New Potential Markers for Intervertebral Disc Degeneration.Journal of oncology · 2022Article
- CircRNA_100269 is downregulated in gastric cancer and suppresses tumor cell growth by targeting miR-630.Aging · 2017Article
- MiR-22 functions as a biomarker and regulates cell proliferation, cycle, apoptosis, migration and invasion in renal cell carcinoma.International journal of clinical and experimental pathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we examined the roles of neurotrophic tyrosine kinase receptor type 2 (NTRK2) gene in regulating in vitro proliferation and invasion in human gastric cancer. Gene expression of NTRK2 was compared between non-carcinoma gastric epithelial cells and gastric cancer (GC) cells by quantitative RT-PCR (qRT-PCR). NTRK2 was either downregulated or upregulated in MKN-28 and SNU-719 cells. The effect of NTRK2 downregulation or upregulation on GC in vitro development was analyzed by qRT-PCR, western blot, proliferation assay, and invasion assay, respectively. The upstream regulator of NTRK2, microRNA-22 (miR-22), was evaluated by dual-luciferase assay. MiR-22 was then upregulated in MKN-28 and SNU-719 cells to examine its regulation on NTRK2 and its encoded protein, tyrosine kinase receptor B (TrkB). In miR-22-upregulated MKN-28 and SNU-719 cells, NTRK2 was further overexpressed to evaluate functional interaction between miR-22 and NTRK2 in GC. NTRK2 was aberrantly upregulated in GC cell lines than in normal gastric cells. In MKN-28 and SNU-719 cells, NTRK2 downregulation inhibited whereas NTRK2 upregulation promoted GC proliferation and invasion in vitro. MiR-22 was verified to be an inverse upstream regulator of NTRK2. In miR-22-upregulated MKN-28 and SNU-719 cells, NTRK2 overexpression partially reversed the miR-22-induced inhibition on cancer proliferation and invasion. NTRK2 is an oncogene and reversely associated with miR-22 in regulating in vitro cancer development in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.